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Integrative analysis of Multiple 
Sclerosis using a systems biology 
approach
Karla Cervantes-Gracia1 & Holger Husi  2,3
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammatory-demyelinating 
events in the central nervous system. Despite more than 40 years of MS research its aetiology remains 
unknown. This study aims to identify the most frequently reported and consistently regulated 
molecules in MS in order to generate molecular interaction networks and thereby leading to the 
identification of deregulated processes and pathways which could give an insight of the underlying 
molecular mechanisms of MS. Driven by an integrative systems biology approach, gene-expression 
profiling datasets were combined and stratified into “Non-treated” and “Treated” groups and 
additionally compared to other disease patterns. Molecular identifiers from dataset comparisons were 
matched to our Multiple Sclerosis database (MuScle; www.padb.org/muscle). From 5079 statistically 
significant molecules, correlation analysis within groups identified a panel of 16 high-confidence 
genes unique to the naïve MS phenotype, whereas the “Treated” group reflected a common pattern 
associated with autoimmune disease. Pathway and gene-ontology clustering identified the Interferon 
gamma signalling pathway as the most relevant amongst all significant molecules, and viral infections 
as the most likely cause of all down-stream events observed. This hypothesis-free approach revealed 
the most significant molecular events amongst different MS phenotypes which can be used for further 
detailed studies.
Multiple sclerosis (MS) is considered the leading cause of non-traumatic disability worldwide in young adults. 
MS is a long-lasting inflammatory disorder characterized by lesions in the central nervous system that give rise 
to progressive neurodegeneration. Globally, 2.3 million people were reported to have MS in 2013 and the overall 
trend is for an increase of its incidence and prevalence amongst the general population1. MS prevalence varies 
among gender and ethnicity, the highest incidence is found in North America and Europe with a ratio of 2:1 
women to men affected with the disease. Additionally, the economic burden of MS treatment and management is 
constantly rising, with a total yearly cost of approximately 40, 000 USD per patient estimated in 2007 as a global 
average2.
Clinically isolated syndrome (CIS) is recognized as an initial single episode of inflammatory demyelination, 
from which 30–70% progress to MS. CIS is the first clinical presentation of the disease in 85% of MS patients3. 
During the initiation of the disease, relapse events of focal inflammatory lesions of the white matter can be 
detected; relapse events are commonly followed by a complete/partial recovery of the lesion. As the disease 
progresses, an expansion of the pre-existing lesions occurs, leading to a high level of neurodegeneration4. The 
International Advisory Committee on clinical trials in MS has defined a phenotype classification system. The 
most common MS phenotype is called RRMS (relapsing-remitting MS) and accounts for 85% of MS cases. RRMS 
is characterized by the initiation of MS events and 75% of these cases evolve into a progressive level called SPMS 
(secondary-progressive MS), where no remission can be observed and continuous neurodegeneration happens. 
Primary-progressive MS (PPMS) accounts for approximately 15% of MS cases. PPMS is characterized by the 
progressive accumulation of disability from onset, usually without any remission events. PPMS cases that present 
recovery events are called primary-remitting MS (PRMS)5.
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Although the nature of MS remains elusive, it’s been reported that MS imply a complex interaction between 
environmental and genetic factors. Several environmental factors have been identified to play a role in MS, includ-
ing lack of vitamin D, smoking and Epstein-Barr virus exposure. Concerning genetic factors, the HLA-DR*1501 
variant is considered the major genetic susceptibility factor. However, most of the genetic factors associated with 
MS are believed to have low to moderate impact6. Aiming for a better understanding of MS genesis, mechanisms 
like mimicry and bystander activation have caught attention (Fig. 1)7, from which the activation of autoreactive 
T-cells and subsequently central nervous system (CNS) autoimmunity can be explained.
Specific myelin detection and its subsequent damage, is due to myelin specific T-cells that are primary effec-
tors in MS pathogenesis8. Myelin specific T-cells are thought to identify self-antigens, containing the signature 
of the myelin sheets. MOG, PLP and MAG are some myelin molecules that have been reported to share peptides 
with pathogens, reason why these autoreactive T-cells are thought to be involved in MS development and progres-
sion8. These T-cells are believed to be activated in the periphery by environmental triggers processed by antigen 
presenting cells (APCs), such as microglia, macrophages, dendritic cells and B cells, and are detected by autore-
active T-cells in complex with genetic factors, following the infiltration of immune cells into the CNS through the 
blood-brain barrier (BBB) and initiation of MS immunopathology (Fig. 2).
Monozygotic twin studies have shown an MS susceptibility rate of around 30%9, giving an insight of the 
increment of MS severity through a direct environmental impact on the genetic background. The most significant 
genes highlighted through genome-wide association studies (GWAS) are related to the HLA class II gene cluster 
displaying clear linkage disequilibrium. Moreover, meta-analysis and follow-up of several MS GWAS studies have 
led to a convincing association of these variants detected with MS. As for class I allele variations, HLA-A*0201 
shows a protective effect, whereas several other class II alleles confer MS susceptibility10. Among non-HLA signif-
icant gene variations associated with MS susceptibility are IL2RA, ILRA7, CYP27B1, MGAT5, MGAT1, STAT3, 
CD40, IRF8, and others. Despite the information that GWAS have provided, it is not completely clear how these 
variations give MS susceptibility11.
Hypothesis-driven approaches have predominated in the search of MS aetiology, albeit with limited success. 
Although GWAS analyses are non-biased approaches, an in-depth data analysis is still lacking, and challenges 
such as replication, sample size and source lead to a poor understanding of the key molecules and processes 
involved in MS progression. The “recent” implementation of integrative approaches for the understanding of 
complex disorders has led to the rise of un-biased new hypotheses to explain diseases. The analysis and inte-
gration of a huge amount of data result in the identification of conserved networks significantly deregulated in 
a determined disorder (hypothesis) across studies, and can be further validated through traditional procedures 
(Fig. 1). This approach is called systems biology and in contrast to traditional methodologies, multiple significant 
molecules from numerous studies (i.e. GWAS, gene expression profiling, proteomics) are integrated and simulta-
neously analysed. By combination of different data it is possible to uncover hidden patterns in datasets giving rise 
to network interaction models, and clearer insights of the mechanisms involved in complex diseases4,5.
This work implements a systems biology approach to produce a clearer view of the deregulated molecular 
mechanisms involved in MS. As an initial framework a Multiple Sclerosis (MuScle) database was constructed to 
Figure 1. Representation of molecular mimicry and bystander activation mechanisms. Molecular mimicry 
(a) is defined where pathogen and self-antigens are believed to share epitopes, and antigen-cross reaction can 
occur through T cell receptors (TCR). Bystander activation (b) can also reach CNS autoimmunity. In this 
process, pathogen or endogenous ligands can activate APCs through Toll-like receptors (TLRs), stimulating 
APCs production of pro-inflammatory cytokines (i.e. IL1, IL6, IL12), over- differentiation and activation of 
autoreactive T-cells.
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help in data management and retrieval. This also gives the possibility to exchange and reuse this data in further 
analyses. An integrative analysis of multiple gene expression profile studies from PBMC of healthy donors, MS 
patients and MS treated patients was performed with publicly available data, by applying statistical filters, specific 
systems biological pipelines and visualisation tools.
Results
GEO searches resulted in 18 datasets (Supplemental Table S1) that were retrieved, including mRNA expres-
sion and miRNA expression profiles. Several comparisons within each dataset were performed due to their 
high heterogeneity (i.e. healthy donors, RRMS, SPMS, PPMS, different treatments regimens) resulting in a total 
of 44 dataset comparisons (Supplemental Table S2). Additionally, we compared our results with differentially 
expressed genes resulting from Epstein-Barr virus (EBV) infected peripheral blood, inflammatory conditions 
due to Mycobacterium tuberculosis (TB) infection, induced allergic reactions and sarcoidosis, and autoimmune 
responses observed in peripheral blood of patients suffering from systemic lupus erythematosus (SLE), rheuma-
toid arthritis (RA), juvenile idiopathic arthritis (JIA) and enthesitis-related arthritis (ERA).
Significance p-value cut-offs (<0.05) were applied to the results of the statistical analyses obtained through 
GEO2R, and log 2 fold-change (FC) cut-offs (log2FC >1 and <−1) to the interrelated dataset groups stratified 
by PCA (Fig. 3), resulting in a total of 35 dataset comparisons. From the “General” group of datasets, 5079 signif-
icant up and down-regulated molecules were identified. The “Non-treated” group consisted of 13 dataset com-
parisons, from which 16 up and down-regulated molecules were shared in more than 20% of all comparisons in 
this group (Table 1). The most significant gene is the ankyrin repeat domain-containing protein 10 (ANKRD10) 
with a 31% of up-regulated frequency among the dataset comparisons. Of these 16 molecules, three were also 
found to be statistically significant in naïve EBV infected peripheral blood after applying thresholding param-
eters, namely C1ORF228, CNTNAP2 and LPP. However two of the three entries showed an opposite trend in 
differential expression between case and control. Further comparison with differentially expressed genes relat-
ing to inflammatory responses showed two molecules of these 16 with similar fold-change trends (CNTNAP2 
and PDE4DIP), and a comparison with autoimmune disease states resulted in an overlap of 6 genes (SCL8A1, 
MALAT1, C1ORF228, CNTAP2, RIF1 and SMAD4), though 3 of these (SCL8A1, CNTAP2 and RIF1) were mod-
ulated in the opposite direction compared to MS.
The remaining 22 datasets, the “Treated” group, contains a cluster of 16 of the most significant molecules that 
are shown in Table 2. Within the 22 dataset comparisons radical S-adenosyl methionine domain-containing pro-
tein 2 (RSAD2) and interferon-induced GTP-binding protein Mx1 (MX1) were the most significant molecules 
with a frequency of at least 50% to be up-regulated across this dataset group. The results in Table 2 were also 
contextualised by comparison to data derived from EBV infected peripheral blood samples. Four (IFI27, ISG15, 
SIGLEC1 and EPSTI1) out of the 16 molecules were also found to be indicative of EBV infection, also showing 
Figure 2. Suggested mechanisms for MS pathogenesis. Through peripheral activation of specific Th1 cells 
and subsequent release of pro-inflammatory cytokines (IL-1, IFN- γ, TNF, IL-12, IL-17), ligands (i.e. CCR6, 
integrins) on T-cell surface and adhesion molecules of BBB endothelial cells (i.e. CCL20) are activated. This 
event allows T-cell – BBB binding and BBB breakdown by matrix metalloproteases secreted by T-cells. This 
event triggers the recruitment of other autoimmune cells. Once in the CNS T-cells secrete pro-inflammatory 
cytokines, activate secretion of chemokines through microglia/macrophages and recruit more autoimmune 
cells. Myelin specific T-cells are thought to be activated through APCs by antigen- HLAII molecule recognition 
and co-stimulatory molecules, which are activated by soluble proteins of degraded myelin and spread its 
epitopes. These events lead to myelin destruction and neurodegeneration.
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the same trend in differential expression between case and control. The comparative analysis with inflammation 
showed an overlap of three molecules (RSAD2, PLSCR1 and EPSTI1), whereas the autoimmune disease group 
displayed a complete overlap with the significant molecules associated with treated MS patient blood samples, 
both in terms of fold-change directionality and similar fold changes apart from EIF2AK2, which displayed either 
an up- or down-regulation in 50% of all significant data points.
ClueGO analyses were performed in order to identify the relation within the statistically significant molecules 
in terms of overlapping or shared pathways and gene ontologies (Fig. 4). The most significant processes that 
showed an inter-connectivity between the most significant molecules with a frequency of at least 20% within 
all the dataset comparisons were chemokine activity, double-stranded RNA binding and single-stranded RNA 
binding gene ontologies, and most prominently the Interferon gamma (IFN- γ) signalling pathway, encompass-
ing C-X-C motif chemokine 10 (CXCL10), 2′-5′-oligoadenylate synthase 1 (OAS1), ubiquitin-like protein ISG15 
(ISG15), guanylate-binding protein (GBP1), interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), 
interferon alpha-inducible protein 6 (IFI6), and interferon-induced, double-stranded RNA-activated protein 
kinase (EIF2AK2). All the molecules included in this analysis were up-regulated.
Lowering of threshold parameters for further exploratory analysis resulted in a total of 97 molecules that were 
included in the subsequent steps with the lowest frequency of 11% within all the dataset comparisons. GO and 
pathway clustering (Fig. 4) showed that the tyrosine-protein kinase JAK2 (JAK2) and the signal transducer and 
activator of transcription 1-alpha/beta (STAT1) were the genes more involved and shared among the pathways 
found. Separately analyses of the groups were performed. The “treated” group had similar results as the general 
analysis. As for the “non-treated” group, no significant gene ontologies associations neither pathways could be 
determined. The following pathway analyses were based on the general molecules and the “treated” ones. Further 
analysis using GeneMania showed three transcription factors (ISRE, IRF7 and IRF) associated with IFN signal-
ling, and STAT3 with Toll-like receptor (TLR) signalling. Physical interactions (protein-protein interactions) were 
found between IFIT1, IFIT2, IFIT3, IFIT5, ISG15, USP18, EIF2AK2, MX1 and STAT1 (Fig. 5). After the associ-
ation of the molecules from the dataset comparisons to a main pathway through term clustering in ClueGO, the 
next iteration step involved analysis of pathway statistical inference and visualisation in PathVisio. The signalling 
pathway of IFN- γ was shown to be the most significant one either in ClueGO and PathVisio analyses. Once the 
pathway was selected, it was then fully filled by the total significant molecules (5079) of the study into the software 
in order to visualise consistencies and inconsistencies in signal cascades and other chained events. Inconsistent 
pathways and sub-cascades were removed from pathway maps and excluded in the following de-novo pathway 
mapping.
The original pathway map of the IFN-γ signalling sourced from WikiPathways and displayed in PathVisio 
was redesigned, in order to fit the molecular relationships of the data and to coherently contextualise the clini-
cal presentations of MS (Fig. 6). The IFN signalling cascade in MS is represented by up/down-regulated mole-
cules of the study and lead to activation of genes associated with immune response induction. The pathway was 
enriched with the molecules that shared IFN TFs that were found through GeneMania. Here, a clear negative 
feedback loop can be observed, in which Ubiquitin-like protein ISG15 (G1P2) induces IFN-γ expression while 
Ubl carboxyl-terminal hydrolase 18 (USP18) inhibits G1P2 activity, explaining the observed down-regulation 
state of IFN-γ.
After the analysis in PathVisio of the “treated” group, the TLR signalling pathway (Fig. 7) was considered the 
most relevant one due to molecular consistency criteria and statistical significance with a high Z-score and per-
muted p-value of less than 0.05. Here, overexpression of proinflammatory molecules, Interleukin-1 beta (IL1B), 
Interleukin-6 (IL6) and Tumor necrosis factor receptor superfamily member 5 (CD40) can lead to T-cell, B-cell 
and monocyte activation and eventually production of immune response, possibly leading to pro-inflammation.
Figure 3. Principal component analysis of all genes and datasets used in this study. The highlighted molecules 
in the variable plot (a) are the most significant ones that influence the model and how they are correlated 
to each other. The samples plot (b) is a graphical representation of the datasets, showing Dem21216829b/
Dem21216829d and Dem22252466Ab/Dem22252466Ad datasets were the most dissimilar ones and were 
removed.
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Discussion
Based on prior knowledge, the objective of this study was to generate a better understanding regarding the molec-
ular mechanisms underlying MS pathophysiology by analysing large-scale transcriptomics data and deciphering 
how the most significant molecules involved in the disease are affecting each other. Although all the individual 
gene expression profiles used in this study have been previously reported and analysed, a combinatorial integration 
of all the data at the systems level can ultimately yield to new biological insights over MS. Due to the high variabil-
ity and uncertainty of molecular identifiers found within databases such as EnsEMBL and UniProt, in this project 
the PADB database was used (www.PADB.org) to harmonise and integrate molecular data. The PADB database 
was chosen due to its accuracy, great coverage and record of different identifiers for each molecule from different 
databases such as UniProt and EnsEMBL, and transcriptomics data platforms (i.e. Affymetrix, Illumina, Agilent).
By analysing the results obtained in the group of “Non-treated” molecules and as a control of our findings, 
it was identified that some of the significant genes up/down-regulated shown in Table 1 have been previously 
associated with MS. C1ORF228, LPP, SSTR2, SLC8A1, DKK3 and SMAD4 have been associated with MS auto-
immune response events, i.e. SSTR2 is a receptor for the neuro-protective molecule ‘somatostatin’ which presents 
a gradual reduction in response to inflammation. The down-regulation of SSTR2 has been associated with high 
cytokine levels/inflammation and progression of the disease12. SMAD4 has also been associated with MS pathol-
ogy, and it was reported that IL10 production from Th1 cells under induction of TGF-β via SMAD4 does occur13. 
IL10 is an anti-inflammatory cytokine that inhibits Th1-effector functions and it is usually increased during 
remission. Its expression can also be induced by MS treatments (i.e. IFNB, glatiramer acetate)14. This event might 
be a possible explanation of the remission stages, where Th1 effector cells produce their own inhibitors. Thus, the 
up-regulation of SMAD4 found in this analysis match and relate to IL10 overexpression. Another gene of interest 
identified in this study is DKK3. Its expression is essential to maintain T-cell controlled activation and to protect 
tissues from self-destructiveness. DKK3 down-regulation has been reported in the experimental autoimmune 
encephalomyelitis (EAE) animal model, where it leads to a local increment of CD8 + T-cell reactivity, which 
worsens the symptoms15.
The remaining molecules (Table 1) have not been associated with MS yet, however most of them have been 
related with synapsis and neuronal processes in the CNS and PBMCs. The most significant one, ANKRD10, 
is involved in the regulation of the canonical-Wnt signalling pathway. Among other roles, its pathway inhibi-
tion promotes myelination, and, when activated, delays the differentiation of precursors into myelin oligoden-
drocytes16. It is notable that generally all ankyrin repeat domain containing molecules have been shown to be 
involved in the formation of transcription complexes, the initiation of immune responses, biogenesis and the 
assembly of protein complexes also linked to cell adhesion, and it is conceivable that this particular molecule is 
an as yet unattributed key player in adhesion. In this analysis, ANKRD10 was observed to be up-regulated in MS 
samples, which can be related with a myelination arrest of MS. MALAT1 has also been related with regulation of 
neurodegeneration. The up-regulation of this molecule protects from retinal neurodegeneration, but in this study 
MALAT1 is down-regulated, therefore potentially associated with other MS symptoms17. Of particular interest 
is also the observed down-regulation of Contactin- associated protein-like 2 precursor (CNTNAP2), which was 
observed both in MS and EBV-infected samples. This molecule is a well-known adhesion molecule that belongs 
to the neurexin family and functions in the vertebrate nervous system as a cell adhesion molecule and receptor. It 
CluSO Gene Name
“Non-treated” group 
(n = 13)
Virus infected group 
(n = 2)
Inflammation group 
(n = 3)
Autoimmune group 
(n = 14)
Regulation logFCa Regulation logFCa Regulation logFCa Regulation logFCa
B0717 ANKRD10 Ankyrin repeat domain protein 10 Up 2.21 (4) nsb nsb nsb
B0384 ADD2 Beta- adducin Up 2.12 (3) nsb nsb nsb
BA289 SLC8A1 Sodium/calcium exchanger 1 precursor Up 3.11 (3)* nsb nsb Down −1.24 (1)
B9374 MALAT1 Metastasis associated lung adenocarcinoma transcript 1 protein Down −1.92 (3)* ns
b nsb Down −1.66 (2)
B1814 C1ORF228 Uncharacterized protein C1ORF228 Up 1.28 (3) Down −1.27 (1) nsb Up 1.66 (1)
BF644 SSTR2 Somatostatin receptor type 2 Down −2.32 (3) nsb nsb nsb
B5523 F5 Coagulation factor V precursor Down −1.4 (3)* nsb nsb nsb
B3266 CNTNAP2 Contactin- associated protein-like 2 precursor Down −3.21 (3)* Down −1.25 (1) Down −1.08 (1) Up 2.03 (1)
BG121 TAF9B Transcription initiation factor TFIID subunit 9B Up 1.91 (3) nsb nsb nsb
B9009 LPP Lipoma preferred partner Up 1.48 (3)* Down −1.64 (1) nsb nsb
BB904 PAWR Prostate apoptosis response protein PAR-4 Down −2.09 (3) nsb nsb nsb
BD727 RIF1 Telomere-associated protein RIF1 Down −1.64 (3) nsb nsb Up 1.38 (1)
BA240 PDE4DIP Myomegalin Up 1.27 (3) nsb Up 1.11 (1) nsb
BF121 SMAD4 Mothers against decapentaplegic homolog 4 Up 1.56 (3) nsb nsb Up 1.2 (1)
BJ537 DKK3 Dickkopf-related protein 3 Up 1.86 (3) nsb nsb nsb
B9548 MDM4 MDM4 P53 binding protein homolog Up 1.58 (3)* nsb nsb nsb
Table 1. Most significant, correlated and deregulated molecules without treatment. *Molecules found to also 
be regulated in the opposite direction, shown in a single dataset; aNumber in brackets denote the number of 
significant occurrences in all samples; bNon-significant.
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is localized at the juxtaparanodes of myelinated axons, where it mediates interactions between neurons and glia 
and has been implicated in many neurodegenerative processes, and is quite likely a key player in other neurode-
generative disorders such as MS.
As for the “Treated” group, most of the significant molecules identified through the statistical filters (Table 2) 
are consistent with previously reported investigations. A study describing biomarkers specific to IFN-β treatment 
activity identified RSAD2, MX1, IFI27, IFI44L, HERC5, SIGLEC1, USP18, EPSTI1 through gene expression pro-
files18,19. These molecules were confirmed to be activated by IFN-β when compared to IFN-γ activity. It was also 
determined that these molecule expressions were decreased in the presence of neutralizing antibodies (NAB). A 
different study reported similar findings by using an integrative approach, but following a different criteria and 
data sources (gene expression profiles, GWAS)16,18. Through these findings it can be established that by using a 
completely unbiased approach it was possible to reach the same outcome as previous studies.
Common gene expression analyses, GWAS, and so on, have problems supporting their results due to small 
number of samples and lack of replication. Here better results were obtained from the “Treated” group than from 
the “Non-treated”, this could be explained due to the sample size, source (PBMC) and the great disease heteroge-
neity. However, through the combination of large data sets from previous studies, these limitations were somehow 
diminished. Moreover, these results should be interpreted under the assumption that the sources of the data are 
PBMC samples, not CNS tissue. Further confirmation that the PBMC molecules found represent CNS events is 
needed.
Concerning the pathway analysis, it is pertinent to keep in mind that these were generated by the inclusion 
of all the dataset comparisons, where the most significant molecules belong to the treated group, simply due to 
the bigger size of experimental studies. Therefore, this is a potential weakness of the study. Since ClueGO could 
significantly assign neither gene ontologies nor pathways to the “Non-treated” molecules, and their Wikipathways 
in Pathvisio were inconsistent, these molecules were combined with the treated ones, leading to Figs 4–7. Instead 
of having a clean and consistent comparison without any external noise, here the final hypothesis could be a 
reflection of the treatments or the pathogenesis of MS. Further analysis should be performed, including higher 
quantities of gene expression profiles, the inclusion of omic’s studies and detailed analyses.
For more than 30 years IFN-γ has been reported as one of the major proinflammatory cytokines found in MS, 
however its role remains uncertain. IFN-γ secretion is thought to be Th1 cells hallmark. NK-cells and APCs also 
produce IFN-γ, which binds to almost all cell types due to its ubiquitously expressed receptor. This double role 
needs to be studied in more depth20,21. Here IFN-γ signalling pathway was the most significant and consistent 
among all the significant molecules of the study. It was considered as the focus-signalling pathway. GeneMania 
results of TFs shared within the molecules showed that most of the molecules involved in this pathway lead to 
immune response. Some gene products can also be described in the IFN-β-signalling pathway. It was shown that 
the signalling and induction of differently expressed genes depends on the cell types, finding a correlation within 
each other to activate the main factors (i.e. cytokines, chemokines) mainly found in MS patients19,22. It has also 
being reported that besides viral induction, IFN-γ T-cells can be activated through IFN-α or β, leading to IFN-γ 
signalling19. Further studies need to be done to identify which agents can activate IFN-γ expression. The observed 
CluSO Gene Name
“Treated” group 
(n = 22)
Virus infected group 
(n = 2)
Inflammation group 
(n = 3)
Autoimmune group 
(n = 14)
Regulation logFCa Regulation logFCa Regulation logFCa Regulation logFCa
BE141 RSAD2 Radical S-Adenosyl methionine domain-containing protein 2 Up 2.52 (14)* ns
b Up 1.35 (1) Up 2.36 (4)
BA153 MX1 Interferon-induced GTP-binding protein MX1 Up 1.92 (11)* nsb nsb Up 1.66 (4)
B7528 IFI44L Interferon-induced protein 44-like Up 2.99 (10)* nsb nsb Up 2.25 (7)
B7546 IFI27 Interferon-alpha inducible protein 27 Up 4.05 (10)* Up 2.25 (2) nsb Up 4.04 (5)
BI124 BIRC4BP XIAP associated factor-1 Up 1.54 (10)* nsb nsb Up 1.54 (3)
B7105 HERC5 Probable E3 ubiquitin-protein ligase HERC5 Up 1.96 (10)* nsb nsb Up 1.73 (6)
B7896 ISG15 Ubiquitin-like protein ISG15 Up 2.15 (10)* Up 1.33 (1) nsb Up 1.98 (6)
BF209 SIGLEC1 Sialoadhesin precursor Up 2.83 (10)* Up 1.95 (1) nsb Up 2.88 (2)
BF513 SPATS2L SPATS2-like protein Up 1.8 (9)* nsb nsb Up 1.76 (4)
BC522 PLSCR1 Phospholipid scramblase 1 Up 1.32 (9)* nsb Up 1.10 (2) Up 1.58 (1)
BH558 USP18 Ubl carboxyl-terminal hydrolase 18 Up 2.58 (9)* nsb nsb Up 2.41 (4)
B4753 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 Up 1.35 (9)* ns
b nsb Up 0.15 (4)**
B7547 IFI44 Interferon-induced protein 44 Up 1.69 (9)* nsb nsb Up 1.88 (5)
B7549 IFIH1 Interferon-induced helicase C domain-containing protein 1 Up 1.44 (9)* ns
b nsb Up 1.1 (4)
BB257 OAS2 2′-5′-oligoadenylate synthase 2 Up 1.56 (9)* nsb nsb Up 1.63 (5)
B5174 EPSTI1 Epithelial stromal interaction protein 1 Up 1.69 (9)* Up 1.26 (1) Up 1.12 (2) Up 2 (2)
Table 2. Most significant, correlated and deregulated molecules after treatment. *Molecules found to also be 
regulated in the opposite direction, shown in a single dataset; **Molecules found to also be regulated in the 
opposite direction, shown in 2 datasets; aNumber in brackets denote the number of significant occurrences in all 
samples; bNon-significant.
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down-regulation can also be studied by, for example, investigating USP18 activity and whether it can be associ-
ated further to a specific cell type and stage of the disease.
Although the main cell types that take place in CNS neurodegeneration have been previously described, their 
precise mechanism is unknown. Moreover, it has been previously reported that IFN-γ influence the expression 
of different molecules in each cell type involve in MS, which can be associated with its dual role in the disease20. 
Since in some of the studies included in this analysis several cell types were isolated (CD4+, CD8+, CD34+), 
Fig. 6 represents a global but specific outcome of IFN-γ induction within different PBMCs and further analysis of 
the significant molecules found in this study can be performed.
Several hypotheses can rise from this pathway, where every up-regulated molecule can be individually vali-
dated. As an example, the overexpression of specific chemokines and cytokines IL1B, CXCL10, CXCL11 that acti-
vate microglia/macrophages, T-cells, B-cells, and others can be compared within MS phenotypes, and ascertain 
if PBMCs can mirror CNS activity. Validation of the significant molecules can include the identification of the 
cell type that produces them, as well as abundance in the CNS of MS patients. These molecules can be compared 
within MS phenotypes to see if there is an expression difference, and a correlation with remission or progression 
of the disease can be reached.
Additionally, the over-representation of the TLR signalling pathway can be associated to MS treatment. The 
significance of this pathway within the “Treated” group of molecules matches the definition of the pathway, where 
its activation is induced through antivirals21. This result shows a probable mis-target of pro-inflammatory mole-
cules induced by treatment (i.e. IFN-β). The validation of these molecules as biomarkers of treatment activity and 
productivity can also be proposed.
Figure 4. Processes and pathways identified within the most significant molecules of the datasets. Gene 
ontology and pathway analysis was performed using significant molecules across all datasets. Node size reflects 
the number of associated molecules, and node colour corresponds to statistical significance. The darker the 
pathway node, the more statistically significant it is, with a gradient from red (p-value 0.05–0.005) to black 
(p-value < 0.0005). Green stars mark the molecules that were also statistically significant associated with innate 
immune response, and blue triangles denote statistically significant virus response molecules. Both latter 
biological function groups were removed from the figure to improve visualisation.
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Taking into account the different analyses carried out, a final hypothesis was generated. Through ClueGO 
pathway analyses and PathVisio validation, IFN-γ is considered the main pathway involved in MS. An activation 
of this pathway through viral load was properly identified by the significant involvement of antiviral pathways 
(Fig. 4). Although a common immune response outcome is expected, the correlation of other pathways was also 
detected. Every pathway associated with the most significant genes (Fig. 8) was previously related with MS patho-
physiology. Oncostatin M has a known role in MS due to the up-regulation of Intercellular adhesion molecule-1 
(ICAM1) in CNS epithelial cells22. It also induces pro-inflammatory IL-6 expression23. Primary focal segmental 
glomerulosclerosis (FSGS) has been reported to be induced by IFN-β and γ treatment24. Aryl hydrocarbon recep-
tor has also been associated with MS and is gaining focus due to the association of the gut microbiota composi-
tion and MS25. AHR has been reported as linked with Th17 and T-regulatory (T-reg) cells and thus, involved in 
immune response regulation, and as for autoimmune diseases, AHR can supress it or make it worse, depending 
Figure 5. Protein-protein interactions and transcription factors associated with main molecules of the study. 
Three transcription factor sites were identified in IFI44, LGALS3BP, CXCL10, DDX58, IFIT2, USP18, EPST11; 
all three are transcription factors are related with IFN signalling. An additional stat3 transcription factor site 
was found in SERPING1 and CCL2. Pink connections represent the physical interaction of molecules.
Figure 6. MS IFN- γ signalling pathway. IFN-γ pathway has been identified as the main pathway involved 
generally in this study through PathVisio analyses. Lines without an arrow mean binding; complete arrows 
mean activation/induction and dashed arrows mean activation through a unknown/more complex process. 
For the genes with question marks “?”, their function remains unclear. The up and down-regulated genes are 
represented in red and Green boxes respectively. The more strong the colour, the more up/down-regulated the 
gene. IFN-γ is down-regulated while the rest of the molecules in the pathway up-regulated possibly due to a 
feedback process with the molecules it induces.
www.nature.com/scientificreports/
9SCIentIfIC RePoRTS |  (2018) 8:5633  | DOI:10.1038/s41598-018-24032-8
on its ligand26. In order to validate and in this way corroborate the results of this study a follow-up experimental 
setup would be necessary.
In order to further contextualise and corroborate the findings in light of the findings regarding the potential 
upstream effector of EBV infection, we compared the observed expression profiles of statistically significant and 
across-dataset correlated molecules to naïve datasets relating only to EBV-infections and peripheral blood. A 
comparison of the most significant molecules involved in MS pathophysiology (Table 1) shows little overlap of 
only three molecules concerning significance, however the dysregulation between case and control of two of these 
three molecules demonstrate a completely opposite trend between MS and EBV infection. This profile between 
MS and EBV is slightly more correlated in the treatment group (4 out of 16 molecules with same dysregulation 
directionality) as shown in Table 2, which is somewhat expected given the target of the pharmacological treat-
ment. Therefore, the observed common molecular pattern in MS, as a result of an upstream event of EBV infec-
tion, is indeed specific to MS pathophysiology and does not reflect the primary infection per se. This is likely due 
to a response further downstream to the infection, and an apparent viral infection by EBV is not the direct causa-
tive agent of the changes we observed. Yet there is mounting evidence that MS is tightly linked to EBV infection, 
whereby viral expression was observed in the CNS of MS cases27,28. It is also of importance to note that EBV is 
capable to express latent endogenous retroviral genes in the human genome, some of which are pro-inflammatory 
and have super-antigenic properties and have been shown to cause neurotoxic effects29. It is not possible to state 
whether EBV infection is the sole contributor or initiator of observed MS-based molecular changes in blood 
based on our analysis, but the literature suggests that multiple health-affecting causes are contributing factors to 
MS pathophysiology and/or initiation events, of which EBV is one of them.
As mentioned above, inflammation and inflammatory responses are intricately linked to the MS pathophysi-
ology30,31. Therefore the MS-derived data was compared with a sarcoidosis dataset, primarily since it was reported 
that prolonged interferon beta treatment of MS patients can induce sarcoidosis32,33. Additionally, a dataset derived 
from allergic reaction was also used as another comparator due to its well characterized panel of modulated mol-
ecules in blood in inflammatory response34, as well as a comparison to infection by TB, which is well known to 
induce inflammatory effects observable in peripheral blood35. The cross-comparison between the significant MS 
data and a general inflammation status showed no considerable or consistent correlation with our observations. 
Only 5 molecules (CNTNAP2, PDE4DIP, RSAD2, PLSCR1 and EPSTI1) out of 32 showed a significance and 
similar fold-change trend compared to the MS data. PLSCR1 and members of this gene family were shown to 
be activated during acute phase responses36, and EPSTI1 has been reported to be involved in inflammatory gene 
expression regulation in macrophages37, but no substantial overlap between inflammatory conditions and MS 
could be demonstrated within the MS-specific molecules. Therefore, it is reasonable to assume that the correlated 
and statistically significant molecules presented in this study do not represent an inflammatory status observable 
in other investigations.
Figure 7. MS TLR signalling pathway. Toll-like receptor signalling pathway was identified through the 
treatment group molecules and filled with the entire set of significant molecules found in the study; it was 
personalized in PathVisio WikiPathways and complemented with GeneMania results. A brief explanation of 
the final products function is described. Arrows mean activation/induction; dashed arrows mean activation 
through a unknown/more complex process. The genes up-regulated in this study are represented in red boxes, 
the more red, the more up-regulation they present.
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Another, and very important, facet regarding the aetiology of MS is the well described autoimmune disease 
aspect. Therefore the data derived from the MS analysis was compared to specific other autoimmune diseases, 
namely SLE, RA, JIA and ERA. SLE is a multisystemic autoimmune disease that can manifest itself in numerous 
pathological outcomes affecting skin, joints, lung, kidney and the CNS38. Indeed, it was reported in the litera-
ture that demyelinating disease in SLE in particular has the propensity to be accidentally misdiagnosed as other 
CNS affecting diseases such as MS39, and a case report showed an induction of SLE by interferon beta-1 treat-
ment of a MS patient40, thereby demonstrating the potential autoimmune-link between these two diseases. RA, 
JIA and ERA are joint-affecting autoimmune disorders and are, like SLE, underpinned by chronic inflamma-
tion41. Large-scale GEO data retrieval and statistical analyses, followed by correlation to the MS results showed 
an overlap of 6 out of the 16 MS-specific molecules in the untreated MS-group, though 50% of these molecules 
(SCL8A1, CNTAP2 and RIF1) displayed an opposite fold-change in the case-control setting, and the other half 
(MALAT1, C1ORF228 and SMAD4) the same modulated directionality in the disease condition. This marginal 
overlap, confounded by dissimilar dysregulation, demonstrates to a considerable extent the specific nature of the 
MS-associated significant molecules which are distinct from modulated events observable in an autoimmune 
condition. However, a comparison and correlation of the autoimmune disease datasets with the treated MS-group 
shows a 100% correlation and association between both. This result shows that the molecular profile obtained 
from the treated MS-group is indistinguishable from the autoimmune condition group, and thereby constitutes 
the generic molecular response of MS disease pathophysiology observable in blood samples. It is quite feasible 
that this generic response has been “hidden” or overshadowed by the specific response observed in the untreated 
samples, especially since it is extremely unlikely that pharmacological treatment of MS patients would result in a 
molecular phenotype resembling or mimicking an autoimmune disease.
Additionally, to link autoimmune disease to viral attack, it was reported that EBV infection correlates epide-
miologically with MS, SLE and RA, though the mechanism is as yet unknown, and whether EBV is a causative 
agent or to what level it contributes to an autoimmune response is still under debate42.
In summary, based on the large-scale data and molecular correlation analysis shown here, viral infection as 
well as inflammation are not the primary cause of molecular changes observed in MS blood samples. It can also be 
reported that key molecules, consistent and statistically significant, associated with untreated MS blood samples do 
not reflect a molecular composition in terms of gene modulation of autoimmune disease (mainly SLE). Yet there is 
clear evidence that pharmacological treatment of MS with appropriate compounds results in a molecular modulated 
pattern of specific, statistically significant and correlated molecules overlapping with the pattern observed in autoim-
mune disease. This might be due to “unmasking” by removal of MS-associated specific molecular changes observed 
in the untreated group after disease treatment. This would also explain why an overlap between the most consist-
ent and statistically significant molecules in both MS untreated and treated analyses was not observed, whereby 
MS-specific responses can be attributed to the modulated changes of molecules listed in Table 1, and generic 
responses, in particular auto-immune disease, is reflected by the panel of molecular changes shown in Table 2 of 
the manuscript. One possible mechanistic interpretation of these findings is that pharmacological treatment of MS 
Figure 8. Multiple sclerosis pathway. IFN-γ signalling is activated by viral load and produced immune 
response; other pathways are thought to be involved in the significant gene response, however pathway names 
can be unrelated with MS at all. Gene ontologies can be highlighted just for those pathways were those genes 
have been identified.
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patients with interferon beta silences specifically the effects caused by EBV infection, yet does not modulate the 
autoimmune response effect. This is substantiated by the findings that interferon beta induces anti-inflammatory 
cytokines and represses HERV43, whose expression is directly linked to the presence and activity of EBV.On matters 
of validation targets selection, both the most significant molecules of the “Non-treated”/“Treated” groups as well as 
the processes and molecules involved in the IFN-γ signalling pathway and in the final hypothesis can be considered 
as potential novel targets. These molecules can be evaluated within MS patients with different phenotypes (CIS, 
RRMS, SPMS, PPMS), and a specific interval of time, in order to establish a possible link between molecules, path-
ways and phenotypes. Further association analysis of these molecules with other diseases should be carried out. If 
there’s a great overlap within other disorders, a panel of potential biomarkers can be developed.
By following a logic criterion, under statistical evaluation and through a completely unbiased approach, it was 
shown its assertiveness. It was possible to identify some consistent molecules among the studies that were pre-
viously associated with MS aetiology and new ones, as well as the identification of potential pathways associated 
with the disease, however it is evident that other important molecules and elements exist in the MS aetiology that 
could not be uncovered by the approach used here due to heterogeneity and other influencing factors. Through 
this analysis presented here, the results obtained in this study might give a starting point to establish traditional 
approaches by knowing in which processes to focus, opening a huge amount of possibilities to explore.
Methods
Dataset Identification. Human transcription profiles were identified and retrieved from the Gene 
Expression Omnibus (GEO) database44. ‘Multiple sclerosis’ and ‘Peripheral blood’ were used as key words for the 
first search and “miRNA” was used additionally for queries of miRNAs studies. A total of 18 datasets between gene 
transcription profiles (11) (GEO expression datasets GSE53716, GSE26484, GSE16461, GSE26104, GSE24427, 
GSE23205, GSE21942, GSE23832, GSE5574, GSE27688 and GSE43591) and miRNA transcription profiles (7) 
(GSE21079, GSE74579, GSE43590, GSE46282, GSE46283, GSE27690 and GSE17846) were obtained and further 
analysed through GEO2R. GEOR2 is a statistical package embedded in GEO that was used to compare groups 
of GEO datasets (e.g. healthy vs. disease). Two main groups across all datasets were analysed, namely healthy 
against disease and disease against disease treated. Comparative datasets for EBV infection (2 datasets) (GEO 
expression datasets GSE45918 (8 case and 8 control samples) and GSE45919 (15 case and 9 control samples)), 
inflammation data (3 datasets) derived from allergic reaction (GSE1964 (46 case and 37 control samples)), sac-
roidosis (GSE19314 (38 case and 20 control samples)) and TB infection (GSE28623 (46 case and 37 control 
samples), omitting non-symptomatic but TB positive patients) and autoimmune diseases (10 datasets) including 
SLE (GEO expression datasets GSE10325, GSE45923, GSE55447, GSE30153, GDS4185, GSE50395, GSE51997, 
GSE20864, GSE17755, GSE1964 (352 cases and 230 controls in total)), RA (GSE17755 and GSE1964 (120 cases 
and 61 controls)), JIA (GSE17755 (57 cases and 53 controls)) and ERA (GSE1964 (15 case and 8 control samples)) 
were identified and processed in a similar fashion.
GEOR2 performs a Student t-test statistical analysis (p-value calculation, as well as other output parameters 
such as fold-changes), generates tables of gene expression comparison between the chosen groups and sorts the 
molecules by significance. P-values were adjusted using Benjamini-Hochberg (BH) correction45. In case of a sta-
tistically poor dataset, where adjusted p-values were greater than 0.05, the unadjusted values were used.
Data processing. All datasets were processed simultaneously. The molecules from the dataset compar-
isons were cross-mapped to the Pan-omics Analysis DataBase (PADB)46 in order to harmonise all data in a 
non-redundant fashion and for the purpose of cross-mapping to other databases (i.e. EnsEMBL, Uniprot, Gene 
names) using an in-house software (AWASH). Non-matched molecular identifiers were additionally covered 
using BioMart47.
Only molecules with a significant p-value of less than 0.05 for each comparison were kept. These molecules 
were subsequently used via further manual curation to develop a database named MuScle. The generated database 
is publicly available at www.PADB.org/muscle/ (See Supplementary Figure S1), it links to several external molec-
ular identifiers (i.e. EnsEMBL, Uniprot/SwissProt, Gene ID, UniGene, OMIM) and to biomedical literature publi-
cations by PubMed identifiers. The database storages and integrates information regarding the experimental setup 
of the studies (sample characteristics, processing and detection), molecular information (such as external data-
base identifiers, names, regulation in the disease and statistical scores) and links to the clinical information of the 
studies (cohort size, number of cases and controls, type of treatment administered and other clinical parameters).
All datasets were merged using the in-house AWASH software. Within each dataset, the repeated molecules 
were either averaged or removed when fold-change values were observe to be oppositely regulated. Further 
thresholding involved a cut-off value of a log 2 fold change (log2FC) with a log2FC >1 and <−1.
We carried out dimensionality reduction through Principal Component Analysis (PCA) using Multibase 
(Numerical Dynamics, Japan, 2015) to enable filtering, such as outlier removal, and rearrange or remove samples 
based on patterns of gene expression across all the datasets comparisons. After plotting the variables (loadings), 
inconsistent datasets were removed and the remaining datasets were split into the distinct groups based on the 
PCA. The first includes all the dataset comparisons (“General” group), the second includes the dataset compar-
isons that fitted the healthy (control) versus disease group (“Non-treated” group) and the third handles dataset 
comparisons that fitted the disease treated (control) versus disease group (“Treated” group).
Functional analyses. Functional analyses of the three groups were carried out. Gene ontology (GO) and 
pathway term clustering using ClueGO v2.4 and CluePedia version 1.5, and the Cytoscape network analysis 
framework were performed. The default parameters were used with an overall statistical significance value set to 
p-value < 0.05.
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From the total molecules a frequency threshold was applied, keeping as the most significant the ones above 
20% of frequency among the datasets (Table 3). For each of the groups created (general, treated, non-treated) sev-
eral ClueGO analyses were performed, each of it with wider thresholds. GO analysis for biological processes was 
performed and pathways were determined by mapping the molecules tagged into WikiPathways.
Group G consists of all molecules across all samples, Group HD is based on the comparison between 
healthy and MS patients (“untreated”) and Group DD consists of MS samples and samples from treated patients 
(“treated”). The threshold value corresponds to frequency % of molecules observed in specific groups and is 
shown in brackets after the number of molecules in each group.
Pathway analyses. Visualisation and pathway statistical inference was carried out in PathVisio 3 and the 
human collection of pathways from WikiPathways. The most significant molecules were imported into PathVisio 
and pathway statistical analysis was performed. First, the most significant molecules were analysed by mak-
ing a table where the EnsEMBL ID, frequency (absolute values) and logFC were included. Once imported into 
Pathvisio, statistical analyses were done and the molecules were mapped; a specific threshold value for frequency 
and logFC needed to be entered for the analyses to begin. For visualization, the options were changed into a col-
our gradient from red to green, from 2 to −2 as for logFC values.
This primary analysis in PathVisio was done in order to identify and compare the most significant pathways 
with the analysis results of the pathway term clustering from ClueGO. Once the pathways were identified and 
converging on both analysis tools, all the significant molecules were added into the PathVisio software in order 
to fill the gaps of these pathways.
To enrich and generate the final original MS pathways, GeneMania was used to display protein–protein inter-
actions (PPI’s) and to identify regulatory elements such as transcription factors (TF’s) across the most significant 
molecules. The results of the several bioinformatics iterations used in the study workflow (Fig. 9) were combined 
and a final hypothesis was generated using validation by deep-mining of the literature. The description and cita-
tion of the previous tools and software solutions used in this integrative systems biology pipeline can be found 
elsewhere48, otherwise they are cited within text.
Threshold Group G Group HD Group DD
1ST 37 (>20%) 19 (>23%) 72 (>23%)
2ND 52 (>17%) 66 (>15%) 93 (>18%)
3RD 72 (>14%) 134 (>14%)
4TH 97 (>11%)
Table 3. Number of molecules per threshold applied for each group.
Figure 9. Summary of the methodology followed in this study. The arrows depict the flow of the various steps. 
ClueGO/CluePedia, PathVisio and GeneMania analysis results were merged in order to generate the initial and 
final hypothesis.
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